FDA-cleared Alzheimer's blood tests are not general screening tools for the public—they're designed specifically for people already showing signs of memory loss or cognitive decline. These tests help doctors rule out or confirm Alzheimer's-related brain changes in symptomatic patients, but they carry no approved use for screening asymptomatic populations, and they cannot predict whether a cognitively healthy person will develop dementia. The two FDA-cleared tests, Fujirebio's Lumipulse G (approved May 2025) and Roche's Elecsys pTau181 (approved October 2025), serve a narrow clinical role: as diagnostic tools for symptomatic patients or as triage tests in primary care. This distinction matters because the approvals come with explicit restrictions that limit who should be tested and why.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Check eligibility on FDA’s official study page — Use this page to check the study’s participation requirements.
- Read the official guidance from Roche — Use this primary source to verify the official guidance.
Table of Contents
- What the FDA Approval Actually Restricts
- Why Asymptomatic People Shouldn't Be Tested
- What These Tests Actually Do
- What a Reader Should Know Before Testing
- The Limits of Blood Biomarkers for Risk Prediction
- Frequently Asked Questions
What the FDA Approval Actually Restricts
The fda clearance for these tests does not mean they can be used on anyone who wants to know their risk. The FDA approval notice explicitly states that neither test carries an indication for general screening of asymptomatic individuals.
The lumipulse G targets patients age 55 and older who already have cognitive decline in specialized care settings, while the Elecsys pTau181 is restricted to patients "presenting with signs, symptoms or complaints of cognitive decline" in primary care—a triage tool, not a population screening test. A positive result in someone with no symptoms sits in medical limbo. This limitation exists because a biomarker alone, without cognitive symptoms, doesn't yet have a clear clinical meaning or treatment path.
Why Asymptomatic People Shouldn't Be Tested
A person who feels cognitively normal but has a positive blood biomarker has no approved treatment to pursue. The approved disease-modifying drugs for Alzheimer's—lecanemab and donanemab—work only in early symptomatic disease, not in asymptomatic individuals with amyloid buildup.
Without a treatment to offer, testing creates anxiety without actionable next steps. The National Institute on Aging and Alzheimer's Association provide no clinical guidance supporting biomarker testing in asymptomatic people outside research. This means if a provider offered you this test "just to know your risk," they would be going beyond both FDA approval and current medical consensus.
What These Tests Actually Do
Both approved tests excel at ruling out or confirming Alzheimer's pathology in people who already have cognitive symptoms. The Elecsys pTau181 has a 97.9% negative predictive value, meaning if the test is negative in a symptomatic patient, it's highly reliable for ruling out amyloid-related changes. The Elecsys pTau181 was specifically designed as a triage tool in primary care: to rule out Alzheimer's pathology in symptomatic patients before specialist referral. These tests measure whether amyloid and tau proteins—hallmarks of Alzheimer's pathology—are present, not whether dementia is coming.
What a Reader Should Know Before Testing
If you're experiencing memory loss, difficulty concentrating, or other cognitive changes, these tests may be relevant in a doctor's office as part of a diagnostic evaluation—but only if your doctor orders them. Requesting one "to be safe" when you have no symptoms doesn't align with FDA guidance or clinical evidence.
Both tests must be interpreted alongside cognitive assessment, medical history, and neurological exam; neither is a standalone screening tool. If a provider offers one without also evaluating your actual cognitive function and symptoms, that's a red flag. A negative result doesn't guarantee you won't develop cognitive decline from other causes, and a positive result in a healthy person doesn't predict future dementia.
The Limits of Blood Biomarkers for Risk Prediction
Some older adults with amyloid and tau changes never develop dementia in their lifetime, while others progress quickly—genetics, education, cardiovascular health, and cognitive reserve all matter. A blood test cannot predict which category you fall into.
The test manufacturers and FDA explicitly state these tests cannot tell cognitively normal individuals whether dementia will develop, which is why asymptomatic screening remains research-only. The presence of biomarkers is necessary but not sufficient for predicting dementia—it's one piece of biology among many.
Frequently Asked Questions
Can I get an FDA-cleared Alzheimer's blood test from my primary care doctor?
Only if you're reporting cognitive symptoms or concerns. The Elecsys pTau181 is approved for primary care use in patients with symptoms. If you have no symptoms, it's not indicated.
What if the blood test is negative—does that mean I won't get Alzheimer's?
A negative test in a symptomatic person reliably rules out Alzheimer's pathology as the cause of symptoms. It doesn't guarantee you won't develop cognitive decline from other causes, and it has no meaning if you're asymptomatic.
My parent has memory loss—would this blood test help?
Yes, possibly. If your parent has cognitive symptoms, a doctor can use the approved blood test alongside cognitive testing to help determine whether Alzheimer's pathology is involved, which can guide treatment eligibility.
Why can't I just get tested for peace of mind if I'm healthy?
Testing asymptomatic people goes against FDA guidance because there's no approved treatment for asymptomatic amyloid positivity. A positive result would cause anxiety without any medical action to take.
